acceleron pharma fell by 8%.e would see merck take control of a potentially lucrative hypertension drug. shery: that is it for "daybreak australia." "daybreak asia" is next. this is bloomberg. ♪ it's moving day. and while her friends are doing the heavy lifting, jess is busy moving her xfinity internet and tv services. it only takes about a minute. wait, a minute? but what have you been doing for the last two hours? ...delegating? oh, good one. move your xfinity services without breaking a sweat. xfinity makes moving easy. go online to transfer your services in about a minute. get started today. haidi: hello and welcome to "daybreak asia." sophie: we are counting down to asia's major market opens. shery: our top stories this hour -- asian traders way a week and to the u.s. trade session. the dollar hitting a 12-month high as investors look for havens. china evergrande

mark has agreed to ash -- merck has agreed to buy xl around -- to buy acceleron pharma.he move is seen as strengthening merck's cardiovascular pipeline. the faa has given richard branson's company the green light to resume flights to the edge of space. virgin galactic made changes to the company policy after the vehicle veered off course carrying branson and others. global news 24 hours a day, on air and on bloomberg quicktake, powered by more than 2700 journalists and analysts in more than 120 countries. i'm ritika gupta. this is bloomberg. ♪ rep. pelosi: i spent a good deal of time in the meeting talking about the debt ceiling because we have to get that done. it would be $15 trillion in household elf that would go down the drain. unemployment would go up to 9%. the president is negotiating. we are hoping we can come to a place. it is not about a dollar amount. jonathan: speaker pelosi on the effort down in washington. from new york this morning, good morning. your equity market up 19 on the s&p, two hours away from the opening bell, the final trading day of q3. we adv

merck has agreed to buy acceleron pharma in a deal that is worth a total of $11.5 billion.he takeover is seen as strengthening merck's cardiovascular pipeline. global news 24 hours a day, on air and on bloomberg quicktake, powered by more than 2700 journalists and analysts in more than 120 countries. i'm ritika gupta. this is bloomberg. ♪ >> the markets are going to pay much less attention to q3 results, much more attention to q4 and 2022 outlook. and yes, supply chain issues are a concern, but they are going to fade. asia is reopening. the port backlogs are going to ease. all of that stuff is temporary. it is not permanent. that provides a tailwind to the upside. jonathan: jay pelosky of tp w has a message area 2021 is over him. he's looking to 2022. good morning. your equity market up about 0.3% on the s&p, one hour and 12 minutes away from the opening bell, as we round out q3. yields are higher by a couple of basis points to 1.5358% on tens. euro-dollar, $1.1579, -0.16%. down in the sea, there's a fight. and senator manchin has this to say, "fiscal insanity." democrats f

just took over july 1 and spending $11.5 billion to buy acceleron pharma for a phase three drug for pulmonaryerial typer tension and had to ask him about upcoming data for the pill they licensed from ridgeback bio. here's what he said about the expectations or his hope for what that drug could do for this pandemic. >> it is something where we think if we can give iterly in the course of the disease it takes it from the devastating disease that covid-19 is to something that's manageable and so important why because it is a pill it is something that obviously can be quite accessible to the general population so we're excited about this because i do think it can really change the way people will think about covid-19 if they're unfortunate enough to be facing it themselves. >> and the moment of truth for this pill is potentially weeks away they're expecting data by november, perhaps sometime in october, filing for emergency use authorization by the end of the year and fingers crossed it works and more in the pipeline from pfizer, as well guys >> yeah. we need good news on all those thank you. >>>

they struck a deal to make the drugmaker acceleron pharma. goes through. >>> speaker pelosi quietly used the $3.5 trillion spending to tuck in massive fines for companies that violate the vaccine mandate. edward lawrence at the white house. we're not talking peanut fines here. substantial fines. reporter: substantial fines. you will love this stu. you thought vaccine mandates itself were bad but now the biden administration would like to crush the businesses that don't follow the vaccine mandate or any osha rule. in the rick sill ages bill osha could get a windfall for a fine. the fine for serious infraction violating the vaccine mandate would go to $70,000 per offense. for repeat violations the fine would be $700,000. osha says the current fine of 13,500 is not enough to motivate large employers. critics think the osha mandate is not legal. what could map the fines could force smaller, medium-sized businesses to close. white house press secretary says mandates work. >> for the most part we have not seen a max exodus in employees. yes individ

this morning, merck announcing a deal to buy acceleron pharma the founder of acceleron, i know theird the giants in the field. i was actually looking at it that's why i was a little bit distracted really amazing that it's a cambridge, mass, company, founded by two guys genetics institute in 1980s is one of the first biotech firms. it was very controversial at the time i'll let you get to the merck ceo. we're excited to have him on thanks for doing with this >> joe, distracted by science is always okay to me. rob davis joins us, the ceo of merck. tell us about the deal for 11.5 billion for acceleron. what does it signal for your strategy for merck going forward? >> first of all, meg, thank you for having me on it's an exciting day for the company. frankly, it's an exciting day for patients with pulmonary hypertension this is a devastating disease. if you look at it at seven years, patients have 50% mortality. first and foremost, we are so excited to join with acceleron and really help deliver for these patients that still have importance feed. if you look at this, why we're so excited